Download PDF
Nuklearmedizin 2022; 61(01): 33-41
DOI: 10.1055/a-1585-7215
Original Article

Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial

Eine Behandlung mit Resveratrol führt nicht zu einer Reduktion der arteriellen Entzündung bei Männern mit einem erhöhten Risiko für Typ-2-Diabetes: Eine randomisierte Crossover-Studie
Ellen Boswijk
1   Department of Radiology and Nuclear Medicine, Maastricht UMC+, Maastricht, Netherlands (Ringgold ID: RIN199236)
2   Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands (Ringgold ID: RIN5211)
,
Marlies de Ligt
3   Department of Nutrition and Movement Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, Netherlands (Ringgold ID: RIN5211)
,
Marie-Fleur J Habets
3   Department of Nutrition and Movement Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, Netherlands (Ringgold ID: RIN5211)
,
Alma M.A. Mingels
4   Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht UMC+, Maastricht, Netherlands (Ringgold ID: RIN199236)
,
Wouter D. van Marken Lichtenbelt
3   Department of Nutrition and Movement Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, Netherlands (Ringgold ID: RIN5211)
,
Felix M. Mottaghy
1   Department of Radiology and Nuclear Medicine, Maastricht UMC+, Maastricht, Netherlands (Ringgold ID: RIN199236)
5   Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany (Ringgold ID: RIN39058)
,
Patrick Schrauwen
3   Department of Nutrition and Movement Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, Netherlands (Ringgold ID: RIN5211)
,
Joachim E. Wildberger
1   Department of Radiology and Nuclear Medicine, Maastricht UMC+, Maastricht, Netherlands (Ringgold ID: RIN199236)
2   Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands (Ringgold ID: RIN5211)
,
Jan Bucerius
1   Department of Radiology and Nuclear Medicine, Maastricht UMC+, Maastricht, Netherlands (Ringgold ID: RIN199236)
2   Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands (Ringgold ID: RIN5211)
6   Department of Nuclear Medicine, Universitätsmedizin Göttingen, Gottingen, Germany (Ringgold ID: RIN27177)
› Author AffiliationsThis study was partially funded by the Weijerhorst Stichting, Maastricht, the Netherlands (E.B., J.E.W., J.B.), a project grant (2012.00.1525) of the Diabetes Fund, Amersfoort, the Netherlands (M.d.L., P.S.) and the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, Den Haag, the Netherlands (CVON2014-02 ENERGISE) (M.d.L., P.S.). DSM Nutritional Products Ltd. provided the resveratrol and placebo capsules.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Purpose Resveratrol has shown promising anti-inflammatory effects in in vitro and animal studies. We aimed to investigate this effect on arterial inflammation in vivo.

Methods This was an additional analysis of a double-blind randomized crossover trial which included eight male subjects with decreased insulin sensitivity who underwent an 18F-fluoroxyglucose (18F-FDG) PET/CT after 34 days of placebo and resveratrol treatment (150 mg/day). 18F-FDG uptake was analyzed in the carotid arteries and the aorta, adipose tissue regions, spleen, and bone marrow as measures for arterial and systemic inflammation. Maximum target-to-background ratios (TBRmax) were compared between resveratrol and placebo treatment with the non-parametric Wilcoxon signed-rank test. Median values are shown with their interquartile range.

Results Arterial 18F-FDG uptake was non-significantly higher after resveratrol treatment (TBRmax all vessels 1.7 (1.6–1.7)) in comparison to placebo treatment (1.5 (1.4–1.6); p=0.050). Only in visceral adipose tissue, the increase in 18F-FDG uptake after resveratrol reached statistical significance (p=0.024). Furthermore, CRP-levels were not significantly affected by resveratrol treatment (p=0.091).

Conclusions Resveratrol failed to attenuate arterial or systemic inflammation as measured with 18F-FDG PET in subjects at risk of developing type 2 diabetes. However, validation of these findings in larger human studies is needed.

Zusammenfassung

Ziel Resveratrol hat in In-vitro- und Tierstudien vielversprechende anti-inflammatorische Effekte gezeigt. Unser Ziel war es, diese Wirkung auf die arterielle Entzündung in vivo zu untersuchen.

Methoden Es handelte sich um eine zusätzliche Analyse einer randomisierten Doppelblind-Crossover-Studie, an der acht männliche Probanden mit verminderter Insulinsensitivität teilnahmen, die sich nach 34 Tagen Placebo- und Resveratrol-Behandlung (150 mg/Tag) einer 18F-Fluoroxyglucose (18F-FDG)-PET/CT unterzogen. Die 18F-FDG-Aufnahme wurde in den Karotiden und der Aorta, Fettgeweberegionen, Milz und Knochenmark als Maß für die arterielle und systemische Entzündung analysiert. Die maximalen „Target-to-Background Ratios” (TBRmax) wurden zwischen Resveratrol- und Placebo-Behandlung mit dem nichtparametrischen Wilcoxon-Vorzeichen-Rang-Test verglichen. Die Medianwerte sind mit ihrem Interquartilsbereich angegeben.

Ergebnisse Die arterielle 18F-FDG-Aufnahme war nach der Resveratrol-Behandlung nicht signifikant höher (TBRmax alle Gefäße 1,7 (1,6–1,7)) im Vergleich zur Placebo-Behandlung (1,5 (1,4–1,6); p=0,050). Nur im viszeralen Fettgewebe war der Anstieg der 18F-FDG-Aufnahme nach Resveratrol statistisch signifikant (p=0,024). Auch die CRP-Werte wurden durch die Resveratrol-Behandlung nicht signifikant beeinflusst (p=0,091).

Schlussfolgerungen Resveratrol konnte die mittels 18F-FDG-PET gemessene arterielle oder systemische Entzündung bei Personen mit einem Risiko für die Entwicklung eines Typ-2-Diabetes nicht abschwächen. Allerdings ist eine Validierung dieser Ergebnisse in größeren Humanstudien erforderlich.

Schlüsselwörter

Resveratrol - arterielle Entzündung - Atheriosklerose - Positronen-Emissions-Tomografie (PET)

Keywords

resveratrol - arterial inflammation - atherosclerosis - positron emission tomography (PET)

Supporting information



Publication History

Received: 27 March 2021

Accepted after revision: 11 August 2021

Article published online:
16 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506
    CrossrefPubMedSearch in Google Scholar
  • 2 Novelle MG, Wahl D, Dieguez C. et al. Resveratrol supplementation: Where are we now and where should we go?. Ageing Res Rev 2015; 21: 1-15
    CrossrefPubMedSearch in Google Scholar
  • 3 Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta 2015; 1852: 1071-1113
    CrossrefPubMedSearch in Google Scholar
  • 4 Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 2015; 1852: 1155-1177
    CrossrefPubMedSearch in Google Scholar
  • 5 Do GM, Kwon EY, Kim HJ. et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008; 374: 55-59
    CrossrefPubMedSearch in Google Scholar
  • 6 Fukao H, Ijiri Y, Miura M. et al. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis 2004; 15: 441-446
    CrossrefPubMedSearch in Google Scholar
  • 7 Vasamsetti SB, Karnewar S, Gopoju R. et al. Resveratrol attenuates monocyte-to-macrophage differentiation and associated inflammation via modulation of intracellular GSH homeostasis: Relevance in atherosclerosis. Free Radic Biol Med 2016; 96: 392-405
    CrossrefPubMedSearch in Google Scholar
  • 8 Matos RS, Baroncini LA, Precoma LB. et al. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq Bras Cardiol 2012; 98: 136-142
    CrossrefPubMedSearch in Google Scholar
  • 9 Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy?. Adv Nutr 2016; 7: 706-718
    CrossrefPubMedSearch in Google Scholar
  • 10 Ponzo V, Soldati L, Bo S. Resveratrol: a supplementation for men or for mice?. J Transl Med 2014; 12: 158
    CrossrefPubMedSearch in Google Scholar
  • 11 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874
    CrossrefPubMedSearch in Google Scholar
  • 12 Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116 (Suppl. 06) 9S-16S
    CrossrefPubMedSearch in Google Scholar
  • 13 Marnane M, Prendeville S, McDonnell C. et al. Plaque inflammation and unstable morphology are associated with early stroke recurrence in symptomatic carotid stenosis. Stroke 2014; 45: 801-806
    CrossrefPubMedSearch in Google Scholar
  • 14 Reeps C, Bundschuh RA, Pellisek J. et al. Quantitative assessment of glucose metabolism in the vessel wall of abdominal aortic aneurysms: correlation with histology and role of partial volume correction. Int J Cardiovasc Imaging 2013; 29: 505-512
    CrossrefPubMedSearch in Google Scholar
  • 15 Figueroa AL, Subramanian SS, Cury RC. et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging 2012; 5: 69-77
    CrossrefPubMedSearch in Google Scholar
  • 16 Tahara N, Kai H, Ishibashi M. et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831
    CrossrefPubMedSearch in Google Scholar
  • 17 Lee SJ, On YK, Lee EJ. et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2008; 49: 1277-1282
    CrossrefPubMedSearch in Google Scholar
  • 18 Tawakol A, Singh P, Rudd JH. et al. Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging. J Am Coll Cardiol 2014; 63: 86-88
    CrossrefPubMedSearch in Google Scholar
  • 19 Fayad ZA, Mani V, Woodward M. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378: 1547-1559
    CrossrefPubMedSearch in Google Scholar
  • 20 Emami H, Vucic E, Subramanian S. et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis 2015; 240: 490-496
    CrossrefPubMedSearch in Google Scholar
  • 21 Emami H, Singh P, MacNabb M. et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging 2015; 8: 121-130
    CrossrefPubMedSearch in Google Scholar
  • 22 Kim EJ, Kim S, Kang DO. et al. Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18f-fluorodeoxyglucose positron emission tomograpic imaging. Circ Cardiovasc Imaging 2014; 7: 454-460
    CrossrefPubMedSearch in Google Scholar
  • 23 Figueroa AL, Takx RA, MacNabb MH. et al. Relationship Between Measures of Adiposity, Arterial Inflammation, and Subsequent Cardiovascular Events. Circ Cardiovasc Imaging 2016; 9: e004043
    CrossrefPubMedSearch in Google Scholar
  • 24 de Ligt M, Bruls YMH, Hansen J. et al. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. Mol Metab 2018; 12: 39-47
    CrossrefPubMedSearch in Google Scholar
  • 25 Sahebkar A, Serban C, Ursoniu S. et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2015; 189: 47-55
    CrossrefPubMedSearch in Google Scholar
  • 26 Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35: 1782-1791
    CrossrefPubMedSearch in Google Scholar
  • 27 Bucerius J, Vijgen GH, Brans B. et al. Impact of bariatric surgery on carotid artery inflammation and the metabolic activity in different adipose tissues. Medicine (Baltimore) 2015; 94: e725
    CrossrefPubMedSearch in Google Scholar
  • 28 Timmers S, Konings E, Bilet L. et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622
    CrossrefPubMedSearch in Google Scholar
  • 29 Tome-Carneiro J, Gonzalvez M, Larrosa M. et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res 2012; 56: 810-821
    CrossrefPubMedSearch in Google Scholar
  • 30 de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?. Biochim Biophys Acta 2015; 1852: 1137-1144
    CrossrefPubMedSearch in Google Scholar
  • 31 Liu K, Zhou R, Wang B. et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2014; 99: 1510-1519
    CrossrefPubMedSearch in Google Scholar
  • 32 Huang H, Chen G, Liao D. et al. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev 2016; 17: 1329-1340
    CrossrefPubMedSearch in Google Scholar
  • 33 Liu Y, Ma W, Zhang P. et al. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 2015; 34: 27-34
    CrossrefPubMedSearch in Google Scholar
  • 34 Wilson T, Knight TJ, Beitz DC. et al. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 1996; 59: PL15-PL21
    CrossrefPubMedSearch in Google Scholar
  • 35 Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661
    CrossrefPubMedSearch in Google Scholar
  • 36 Semba RD, Ferrucci L, Bartali B. et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med 2014; 174: 1077-1084
    CrossrefPubMedSearch in Google Scholar
  • 37 Timmers S, de Ligt M, Phielix E. et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2016; 39: 2211-2217
    CrossrefPubMedSearch in Google Scholar
  • 38 Brasnyo P, Molnar GA, Mohas M. et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106: 383-389
    CrossrefPubMedSearch in Google Scholar
  • 39 Dutta P, Courties G, Wei Y. et al. Myocardial infarction accelerates atherosclerosis. Nature 2012; 487: 325-329
    CrossrefPubMedSearch in Google Scholar
  • 40 Tawakol A, Fayad ZA, Mogg R. et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. Journal of the American College of Cardiology 2013; 62: 909-917
    CrossrefPubMedSearch in Google Scholar